查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1523296

异位性皮肤炎市场报告：2030 年趋势、预测与竞争分析

Atopic Dermatitis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

异位性皮肤炎的趋势和预测

预计到 2030 年，全球异位性皮肤炎市场将达到约 233 亿美元，2024 年至 2030 年复合年增长率为 9.4%。该市场的主要驱动力是技术的快速进步和资金筹措的增加，以及政府对研发支持的增加。全球异位性皮肤炎市场的未来看起来充满希望，医院药房、零售药房和线上药房市场充满机会。

异位性皮肤炎依部位分类

按药物类别、给药方法、分销管道和地区提供全球异位性皮肤炎市场的预测。

异位性皮肤炎市场洞察

Lucintel 预测，由于人们对异位性皮肤炎治疗方法的认识不断提高，生物製药将在预测期内实现最高增长。

由于异位性皮肤炎的高发生率，医院药局将继续成为该市场的最大部分。

由于患者治疗意识的提高以及该地区许多私人製造商的存在，预计北美在预测期内仍将是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球异位性皮肤炎市场预计将达到 233 亿美元。

Q2.市场成长预测是多少：

A2. 2024 年至 2030 年，全球异位性皮肤炎市场预计将以 9.4% 的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动因素是技术的快速进步和资金筹措的增加以及政府对研发的支持的增加。

Q4.市场的主要细分市场是：

A4. 异位性皮肤炎市场前景广阔，医院药局、零售药局和网路药局市场充满机会。

Q5.市场的主要企业是：

A5. 异位性皮肤炎领域的主要企业如下：

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Q6.未来最大的细分市场是什么？

A6.Lucintel 预测，由于人们对异位性皮肤炎治疗方法的认识不断提高，生物製药预计将在预测期内实现最高增长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于患者治疗意识的提高以及该地区存在许多内部製造商，北美将在预测期内继续成为最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球异位性皮肤炎市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球异位性皮肤炎市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类别分類的异位性皮肤炎全球市场
    • PDE-4抑制剂
    • 皮质类固醇
    • 生物製药
    • Calcineurin抑制剂
    • 其他的
  • 依给药方式分類的异位性皮肤炎全球市场
    • 局部的
    • 注射
    • 口服
  • 按分销管道分類的全球异位性皮肤炎市场
    • 医院药房
    • 零售药房
    • 网路药房

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球异位性皮肤炎市场
  • 北美异位性皮肤炎市场
  • 欧洲异位性皮肤炎市场
  • 亚太地区异位性皮肤炎市场
  • 其他地区异位性皮肤炎市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
  • 全球异位性皮肤炎市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球异位性皮肤炎市场的产能
    • 全球异位性皮肤炎市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals
简介目录

Atopic Dermatitis Trends and Forecast

The future of the global atopic dermatitis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global atopic dermatitis market is expected to reach an estimated $23.3 billion by 2030 with a CAGR of 9.4% from 2024 to 2030. The major drivers for this market are swift technological advancement and increase in funding, coupled with a rise in government support for research and development.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Atopic Dermatitis by Segment

The study includes a forecast for the global atopic dermatitis by drug class, mode of administration, distribution channel, and region.

Atopic Dermatitis Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • PDE-4 Inhibitor
  • Corticosteroids
  • Biologics
  • Calcineurin Inhibitors
  • Others

Atopic Dermatitis Market by Mode of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Topical
  • Injectable
  • Oral

Atopic Dermatitis Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Atopic Dermatitis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Atopic Dermatitis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies atopic dermatitis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the atopic dermatitis companies profiled in this report include-

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Atopic Dermatitis Market Insights

Lucintel forecasts that biologic is expected to witness the highest growth over the forecast period due to rise in awareness regarding the availability of treatments for the disease.

Within this market, hospital pharmacy will remain the largest segment due to notable prevalence of atopic dermatitis.

North America will remain the largest region over the forecast period due to growing treatment awareness among the patient population and existence of substantial in-house manufacturers in the region.

Features of the Global Atopic Dermatitis Market

Market Size Estimates: Atopic dermatitis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Atopic dermatitis market size by drug class, mode of administration, distribution channel, and region in terms of value ($B).

Regional Analysis: Atopic dermatitis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, mode of administration, distribution channels, and regions for the atopic dermatitis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the atopic dermatitis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the atopic dermatitis market size?

Answer: The global atopic dermatitis market is expected to reach an estimated $23.3 billion by 2030.

Q2. What is the growth forecast for atopic dermatitis market?

Answer: The global atopic dermatitis market is expected to grow with a CAGR of 9.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the atopic dermatitis market?

Answer: The major drivers for this market are swift technological advancement and increase in funding, coupled with a rise in government support for research and development.

Q4. What are the major segments for atopic dermatitis market?

Answer: The future of the atopic dermatitis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.

Q5. Who are the key atopic dermatitis market companies?

Answer: Some of the key atopic dermatitis companies are as follows:

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Q6. Which atopic dermatitis market segment will be the largest in future?

Answer: Lucintel forecasts that biologic is expected to witness the highest growth over the forecast period due to rise in awareness regarding the availability of treatments for the disease.

Q7. In atopic dermatitis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing treatment awareness among the patient population and existence of substantial in-house manufacturers in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the atopic dermatitis market by drug class (PDE-4 inhibitor, corticosteroids, biologics, calcineurin inhibitors, and others), mode of administration (topical, injectable, and oral), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Atopic Dermatitis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Atopic Dermatitis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Atopic Dermatitis Market by Drug Class
    • 3.3.1: PDE-4 Inhibitor
    • 3.3.2: Corticosteroids
    • 3.3.3: Biologics
    • 3.3.4: Calcineurin Inhibitors
    • 3.3.5: Others
  • 3.4: Global Atopic Dermatitis Market by Mode of Administration
    • 3.4.1: Topical
    • 3.4.2: Injectable
    • 3.4.3: Oral
  • 3.5: Global Atopic Dermatitis Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Atopic Dermatitis Market by Region
  • 4.2: North American Atopic Dermatitis Market
    • 4.2.1: North American Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.2.2: North American Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Atopic Dermatitis Market
    • 4.3.1: European Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.3.2: European Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Atopic Dermatitis Market
    • 4.4.1: APAC Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.4.2: APAC Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Atopic Dermatitis Market
    • 4.5.1: ROW Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.5.2: ROW Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Atopic Dermatitis Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Atopic Dermatitis Market by Mode of Administration
    • 6.1.3: Growth Opportunities for the Global Atopic Dermatitis Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Atopic Dermatitis Market by Region
  • 6.2: Emerging Trends in the Global Atopic Dermatitis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Atopic Dermatitis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Atopic Dermatitis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bayer
  • 7.2: AbbVie
  • 7.3: Incyte
  • 7.4: Novartis International
  • 7.5: Arcutis Biotherapeutics
  • 7.6: Bristol-Myers Squibb
  • 7.7: Regeneron Pharmaceuticals